+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
E

Actively Recruiting

Researchers are evaluating the effect on LDL cholesterol LDL-C and the safety and tolerability of a fixed-dose combination FDC of Laroprovstat and Rosuvastatin in patients who have not previously received lipid-lowering treatment LLT. Laroprovstat is a small molecule developed to reduce LDL-C in the blood, and this Phase III randomized study compares this combination with Laroprovstat alone, Rosuvastatin alone, and placebo in people with hypercholesterolaemia. Participants will be randomly assigned to one of several groups receiving daily oral doses of Laroprovstat, Rosuvastatin at two dose levels, the combination LaroprovstatRosuvastatin at two dose levels, or placebo matching these treatments. The study uses a factorial design and is double-blind, meaning neither participants nor researchers know which treatment is given. Treatment lasts for 8 weeks with assessments focused on changes in LDL-C levels. During the study, participants will attend visits for evaluations including blood tests to measure LDL-C and other cholesterol-related markers such as Apo B, non-HDL cholesterol, and total cholesterol. The main outcome measured is the relative change in LDL-C at 8 weeks. Safety and tolerability will also be monitored throughout. The entire participation period covers the treatment and assessment over the 8-week period.

Age: 18Years - 130YearsAll GendersPhase 3
152 locations
P

Actively Recruiting

Researchers are studying the safety, tolerability, and effectiveness of elecoglipron alone or combined with dapagliflozin compared to placebo in adults with type 2 diabetes mellitus T2DM who are not well controlled with lifestyle changes or other glucose-lowering medications. This Phase III trial aims to better understand how these treatments impact blood sugar control and other health measures. Participants will be randomly assigned to one of four groups elecoglipron at dose level 1 with dapagliflozin placebo, elecoglipron at dose level 2 with dapagliflozin placebo, elecoglipron at one of the studied doses combined with dapagliflozin, or matching placebos for both drugs. All medications are taken orally once daily. The study lasts 40 weeks, during which participants receive their assigned treatment and are monitored. During the study, participants will undergo regular assessments including measurements of blood sugar control HbA1c, body weight, and blood pressure from baseline to Week 40. Researchers will also track the achievement of specific blood sugar targets, weight loss percentages, and the time before needing additional diabetes medication. Safety and tolerability will be monitored throughout the treatment period. The total participation duration is approximately 40 weeks.

Age: 18Years +All GendersPhase 3
149 locations
A

Actively Recruiting

Researchers are evaluating ibuzatrelvir to determine its effectiveness and safety in treating adults and adolescents aged 12 and older who have COVID-19 but are not hospitalized. The study focuses on individuals at high risk of progressing to severe illness. Participants will be randomly assigned to receive either ibuzatrelvir or a placebo, alongside standard care as available locally, with the study lasting approximately six months. Participants will receive either ibuzatrelvir tablets or placebo tablets orally every 12 hours for five days. This is a randomized, double-blind, phase 3 study comparing the investigational drug to placebo. The study allows co-administration of locally available standard treatments. The treatment period is followed by monitoring to assess outcomes related to COVID-19 progression and symptom resolution. During the study, participants will be observed for emergency department visits, hospitalizations, mortality, symptom resolution, and viral load changes over 28 days and up to 24 weeks. Researchers will collect data on medical events, including cardiovascular, renal, and pulmonary complications, as well as Long COVID symptoms. Safety is monitored through adverse event tracking. Overall participation lasts about six months with multiple assessments during this time.

Age: 12Years +All GendersPhase 3
256 locations
S

Actively Recruiting

Researchers are studying the safety and how the body processes the medicine Zavegepant PF-07930207 in children aged 6 to less than 12 years who have a history of migraine for at least 6 months. The study focuses on understanding how the medicine is absorbed, changed, and removed from the body after administration. All participants will receive a single dose of Zavegepant as a nasal spray, with the dose depending on their weight. The spray is given once into one nostril. The study will observe the participants experiences, including possible benefits and unwanted effects, during the treatment period. Participants will be involved in the study for up to 10 weeks, which includes 3 visits to the study clinic and 2 follow-up phone calls. Researchers will collect blood samples to measure the medicines levels in the body at specified times and will monitor safety through vital signs, laboratory tests, and questionnaires on mood and behavior.

Age: 6Years - 11YearsAll GendersPhase 1
14 locations
E

Actively Recruiting

Researchers are studying adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancers who are starting systemic cancer treatments such as chemotherapy or immune checkpoint inhibitors. The purpose is to understand how cannabis and cannabinoid use relates to cancer-related symptoms over one year. This observational study enrolls 2000 participants to explore these associations in community oncology settings. Participants do not receive any experimental treatments but complete surveys and have their medical records reviewed. Assessments occur monthly for up to 12 months, capturing cannabis use, perceived benefits and harms, and adverse effects alongside symptom tracking. There is an optional sub-study for some participants receiving immune checkpoint inhibitors at specific cancer centers. During the study, participants complete monthly surveys either online at home, in clinic, or other locations, and their medical records are reviewed for treatment and symptom information. Researchers measure cancer-related symptoms and cannabis use patterns over time. The study monitors participants for up to one year to evaluate symptom changes and cannabis-related effects, with no intervention administered by the study team.

Age: 18Years +All Genders
491 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the impact of the Cost Communication and Financial Navigation CostCOM intervention on adherence to cancer care and financial burden among patients with malignant solid tumors. This study compares the effects of enhanced usual care and the CostCOM program, which offers financial counseling and resource connections to reduce financial barriers and stress. The study aims to assess cost-related non-adherence, financial hardship, worry, quality of life, and satisfaction with care over 12 months. Participants are randomly assigned to one of two groups one group receives a brochure about financial navigation services, while the other group receives usual financial care plus CostCOM counseling sessions lasting about one hour within 30 days of enrollment and again at 3, 6, and 12 months. Non-patient participants involved in the study complete surveys and participate in in-depth interviews between 15 and 39 months after the first patient enrollment. During the study, patients complete surveys at baseline and at 3, 6, and 12 months to report on financial worry, quality of life, and satisfaction with care. Researchers track adherence to cancer treatment and financial outcomes over one year. Non-patient participants contribute by completing surveys and interviews to provide insights into the use and experience of the CostCOM intervention. The total participation time extends up to 12 months for patients and up to 39 months for non-patient participants.

All AgesAll GendersPhase Not Applicable
391 locations
E

Actively Recruiting

Healthy Volunteer

This trial is studying advanced practice providers APPs who work in cancer care but may not regularly participate in clinical research at community oncology sites. It evaluates whether a mentorship and education program called COACH-APP can improve APPs confidence in their ability to engage in clinical research, known as research self-efficacy. The study aims to see if this program helps APPs integrate more meaningfully into research teams and potentially improves patient care and access to clinical trials. Participants are divided into groups where one receives the COACH-APP intervention, which includes completing a 6-module clinical research workshop over 2 hours, receiving a clinical trials research manual, and participating in five mentoring sessions lasting 15-60 minutes over 12 months. The comparison group receives only access to the workshop and manual for 12 months. Additionally, mentors providing the COACH-APP mentorship and selected research care team members participate in qualitative interviews to assess the interventions impact. During the study, participants complete surveys and interviews to measure changes in research self-efficacy, engagement with the National Cancer Institutes community oncology research program, integration into research care teams, and practice-level study activity over 12 to 24 months. The trial also evaluates the feasibility, acceptability, and appropriateness of the COACH-APP program. Participation involves training sessions, mentoring, surveys, and interviews over a 12-month period with follow-up assessments extending up to 24 months.

Age: 18Years +All GendersPhase Not Applicable
44 locations
S

Actively Recruiting

Researchers are evaluating dosing strategies of CDK46 inhibitors in patients aged 60 and older with hormone receptor positive, HER2 negative metastatic breast cancer. The study compares the standard full-dose approach with a titrated dosing method that starts at a lower dose and increases as tolerated. The goal is to help more older patients tolerate side effects and stay on treatment longer to gain the most benefit from these drugs. Participants will choose either palbociclib or ribociclib combined with endocrine therapy, including aromatase inhibitors or fulvestrant. They will be randomly assigned to either the indicated dosing arm, starting at the full approved dose, or the titrated dosing arm, starting at a lower dose and escalating if well tolerated. The treatment cycles follow a 28-day schedule, with doses given orally on days 1-21. During the study, participants will be monitored for time to treatment discontinuation, toxicities, quality of life, dose adjustments, and healthcare utilization for up to 48 months. Patient-reported outcomes will be collected to understand tolerance better. Telehealth visits and remote consenting are allowed per institutional guidelines, supporting patient convenience throughout the trial.

Age: 60Years +All GendersPhase 3
92 locations
T

Actively Recruiting

Researchers are conducting a Hybrid Type 1 cluster-randomized trial in community oncology practice sites to evaluate an intervention aimed at improving the referral and enrollment of Black and Latino cancer patients into National Cancer Institute-supported clinical trials. This study focuses on measuring how effective the intervention is in increasing patient referrals and accrual while also assessing awareness and knowledge of clinical trials among participants and providers. The trial also includes evaluation of implementation factors and plans for dissemination of the intervention to other community oncology sites and networks. The intervention being studied combines clinical trial navigators with research literacy tools in a SUPPORT toolkit, which includes a website and navigator interaction. Participants are assigned to either usual care or the intervention group receiving the SUPPORT toolkit. This study uses a cluster-randomized, parallel design enrolling approximately 500 Black and Latino cancer patients from community oncology sites affiliated with the NCORP network. Participants will be involved for at least 12 months during which referral and accrual to clinical trials are measured as primary and secondary outcomes. The study also evaluates participant and provider awareness and knowledge of clinical trials. Data will be collected through site evaluations and participant interactions. The trial runs from April 2025 through March 2028 with a primary completion date in August 2027.

Age: 18Years +All GendersPhase Not Applicable
67 locations

1-10 of 11

1